Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance

Shandong University300 enrolled

Overview

The investigator's purpose is to study the population pharmacokinetics of commonly used antimicrobial agents in children of bacterial meningitis with augmented renal clearance and assess dosage individualization feasibility.

The investigator's purpose is to study the population pharmacokinetics of meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid in children of bacterial meningitis with augmented renal clearance and assess dosage individualization feasibility. In this study, the investigator will detect drug concentration in both plasma and cerebrospinal fluid to construct population pharmacokinetics.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Bacterial Meningitis Augmented Renal Clearance

Interventions

meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolidDRUG

The use of antimicrobial agents depends on the clinical practice

Eligibility

Sex: ALLMin age: 2 MonthsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children have been diagnosed with bacterial meningitis with augmented renal clearance (eGFR ≥ 160 mL/(min\*1.73m2)); * Age: 2 months-18 years; * Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and/ or linezolid used as part of regular treatment; * Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid was administered intravenously. Exclusion Criteria: * Patients who die within the treatment cycle; * Severe congenital malformation; * Receive other systemic experimental drug therapy; * Other factors that the researchers consider unsuitable for inclusion.

Locations (1)

Children's Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

The peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.

To detect the peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.

Time frame: at (5-10) minutes after intravenous administration

The random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.

To detect the random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.

Time frame: at (0.5-10) hours after intravenous administration

The trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.

To detect the trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.

Time frame: at 1-2 hours before the next administration

Secondary Outcomes

clinical response

Blood routine examination, cerebrospinal fluid routine examination and infection indicators (C-reaction protein, procalcitonin)

Time frame: Through study completion, an average of 14 days

Central Contacts

Wei Zhao, Phd

CONTACT

86053188383308 zhao4wei2@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.